{
  "meta": {
    "title": "Ini_Cet_Nov_2024",
    "url": "https://brainandscalpel.vercel.app/ini-cet-nov-2024-dceed77a.html",
    "scrapedAt": "2025-11-30T07:36:13.024Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">4 hours </span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">68 hours</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">42 hours </span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">0.9 hours</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A young female weighing 46 kg is on digoxin with a volume of distribution of 6 L/kg, and clearance is 4.6 L/hour. Calculate the half-life of digoxin. </span></p>",
      "unique_key": "DT1317841",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317841,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Since first order kinetics is an exponential process, mathematically, the elimination</p>\r\n<ul>\r\n<li><strong><u>t&frac12; = log 2/k</u></strong></li>\r\n</ul>\r\n<p><strong><u>Where log 2 is the natural logarithm of 2 (or 0.693) </u></strong></p>\r\n<p><strong><u>k is the elimination rate constant of the drug, i.e. the fraction of the total amount of drug in the body which is removed per unit time.</u></strong></p>\r\n<p>It is calculated as:</p>\r\n<p><strong><u>k = CL/V</u></strong></p>\r\n<ul>\r\n<li><strong><u>t&frac12; = 0.693 &times; V/CL</u></strong></li>\r\n</ul>\r\n<p>V = Volume of distribution is 6L/kg and patient&rsquo;s weight is 46 kg hence Volume of distribution effectively is 276 L</p>\r\n<p>CL = Clearance is 4.6 L/hr</p>\r\n<p>Hence,</p>\r\n<p>t&frac12; = 0.693 &times; V/CL</p>\r\n<p>t&frac12; = 0.693 * 276 / 4.6</p>\r\n<p><strong><u>t&frac12; = 41.58 hour = 42 hour</u></strong></p>\r\n<p>As such, <u>half-life is a derived parameter from two variables V and CL, both of which may change independently</u></p>\r\n<p><strong><u>Key Takeaway:</u></strong></p>\r\n<p><strong>The Plasma half-life (t&frac12;) of a drug is the time taken for its plasma Concentration to be reduced to half of its original value. Half-life is a derived parameter from two variables V and CL, both of which may change independently</strong></p>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Praziquantel</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Albendazole</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Mebendazole</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Triclabendazole</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Drug of choice for fasciola hepatica: </span></p>",
      "unique_key": "DT1317844",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317844,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><u>Benzimidazoles </u></strong></p>\r\n<ul>\r\n<li>Although a large number of drugs in the Benzimidazoles class have been synthesized and several have undergone clinical development for treatment of parasitic infections of humans, only two are currently in wide use, namely <strong>albendazole and mebendazole, with triclabendazole being reserved for treatment of liver fluke infection caused by Fasciola hepatica.</strong></li>\r\n</ul>\r\n<p><strong><u>Mechanism of Action </u></strong></p>\r\n<ul>\r\n<li>The primary mechanism of action of the <strong>Benzimidazoles is thought to be inhibition of microtubule polymerization by binding to &beta;-tubulin</strong></li>\r\n<li>The selective toxicity of these agents against helminths results from their <strong>increased affinity for parasite &beta;-tubulin than for the same target in higher eukaryotes.</strong></li>\r\n<li>A range of other biochemical changes occur in nematodes following Benzimidazoles exposure, including inhibition of mitochondrial fumarate reductase, reduced glucose transport, and uncoupling of oxidative phosphorylation.</li>\r\n</ul>\r\n<p><strong><u>Triclabendazole</u></strong></p>\r\n<ul>\r\n<li><strong>Administration of triclabendazole after food enhances its absorption, which might be due to the stimulation of gastric acid secretion, food-induced increase in drug solubility, and/ or altered gastrointestinal</strong> (GI) motility and transit time.</li>\r\n<li>After oral administration, <strong>triclabendazole is rapidly oxidized into two major metabolites, triclabendazole sulfoxide and triclabendazole sulfone and only low concentrations of the parent drug can be detected in plasma.</strong></li>\r\n<li><u>Triclabendazole sulfoxide is the metabolite active against F. hepatica</u></li>\r\n<li>Triclabendazole is used for the treatment of fascioliasis and represents an alternative to praziquantel for treatment of paragonimiasis.</li>\r\n</ul>\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice A) Praziquantel<br /> </strong>Praziquantel is effective against <strong>schistosomiasis and many cestode (tapeworm) infections</strong> but is <strong>not effective against Fasciola hepatica</strong>. While it is used for <strong>paragonimiasis (lung fluke)</strong>, it does not cover <strong>liver fluke infections</strong> effectively.<br /> This option is incorrect because it is <strong>not effective against Fasciola hepatica</strong>.</p>\r\n<p><strong>(Choice B) Albendazole<br /> </strong>Albendazole is a broad-spectrum <strong>benzimidazole</strong> used to treat <strong>nematode (roundworm) infections</strong>, <strong>cysticercosis</strong>, and <strong>hydatid disease</strong>. Although it has some efficacy against <strong>trematodes</strong>, it is <strong>not the first-line treatment for Fasciola hepatica</strong>.<br /> This option is incorrect because <strong>triclabendazole is more effective for liver fluke infections</strong>.</p>\r\n<p><strong>(Choice C) Mebendazole<br /> </strong>Mebendazole is another <strong>benzimidazole</strong> primarily used for <strong>intestinal nematode infections</strong> (e.g., ascariasis, hookworm, whipworm). It has <strong>limited efficacy against liver flukes</strong> and is <strong>not recommended</strong> for Fasciola hepatica.<br /> This option is incorrect because <strong>it is not used for Fasciola hepatica treatment</strong>.</p>\r\n<p><strong><u>Key Takeaway:</u></strong></p>\r\n<p><strong>Benzimidazoles</strong><strong> class of drugs are currently in wide use, namely albendazole and mebendazole, with triclabendazole being reserved for treatment of liver fluke infection caused by Fasciola hepatica. </strong></p>",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, and 4 </span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Only 1 and 2</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3 and 4</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Only 1 and 3</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old patient, a known case of hypertension and diabetes, post-PCI stent placement for NSTEMI last year, is currently on three drugs: aspirin, metoprolol, and atorvastatin. He comes for follow-up, and his lipid profile is as follows: cholesterol is raised, LDL is raised, triglycerides are raised, HDL is normal. Which drugs can be added based on his lipid profile?<br>\r\n1. Ezetemibe, 2. Evolocumab, 3. Gemfibrozil, 4. Bempedoic acid\r\n</span></p>",
      "unique_key": "DT1317846",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317846,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><u>Intestinal Cholesterol Absorption Inhibitor</u></strong></p>\r\n<ul>\r\n<li>Ezetimibe inhibits a transporter involved in intestinal absorption of cholesterol called NPC1L1.</li>\r\n<li>Due to <u>decreased absorption, cholesterol content of the liver decreases and it responds by increasing LDL receptor synthesis.</u></li>\r\n<li>It can be used alone or combined with statins for type IIa and IIb hyperlipoproteinemia.</li>\r\n<li>It is effective in reducing LDL-C in patients with <strong>sitosterolemia</strong></li>\r\n</ul>\r\n<p><strong><u>Bempedoic Acid </u></strong></p>\r\n<ul>\r\n<li><strong>Bempedoic acid, a dicarboxylic acid acts by inhibiting de novo hepatocyte cholesterol biosynthesis.</strong></li>\r\n<li>Its <u>mechanism of action complements statins and other agents that lower LDL-C.</u></li>\r\n<li><strong>The drug is approved as an adjunct to diet and maximally tolerated statin therapy to further lower LDL-C in patients with HeFH or established ASCVD.</strong></li>\r\n<li><strong>A fixed-dose combination of bempedoic acid and ezetimibe is approved for the same indication.</strong></li>\r\n<li>Bempedoic acid also has application in patients who are statin-intolerant.</li>\r\n<li><strong><u>Bempedoic acid is FDA-approved for the treatment of adults with either HeFH or established ASCVD who need additional LDL-C lowering.</u></strong></li>\r\n<li><u>Monotherapy with bempedoic acid results in a 15% to 25% reduction in LDL-C, less than with statins. In combination with ezetimibe, the reduction in LDL-C is around 30%, and triple therapy with a statin reduces LDL-C by 65%. Reduction in HDL-C by bempedoic acid is typically around 5%.</u></li>\r\n<li>PCSK9 Inhibitors Proprotein convertase subtilisin kexin type 9 (PCSK 9) is a protein that binds LDL-receptors and transport them to lysosomes where these are degraded.</li>\r\n<li>Therefore instead of recycling of LDL-R to surface of hepatocytes, they get destroyed.</li>\r\n<li>Inhibitors of PCSK 9, therefore prevent destruction of LDL-R resulting in lowering of LDL-cholesterol.</li>\r\n<li><strong>Alirocumab </strong>and <strong>evolocumab </strong>are monoclonal antibodies against PCSK 9 and are approved for familial hypercholesterolemia as an adjunct to diet and maximally tolerated statin therapy.</li>\r\n</ul>\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice B) Only 1 and 2</strong> - This choice includes ezetimibe and evolocumab but omits bempedoic acid, which is beneficial for LDL reduction in patients with ASCVD on maximally tolerated statins.</p>\r\n<p><strong>(Choice C) 1, 3, and 4</strong> - Gemfibrozil (choice 3) is a fibrate that lowers triglycerides but is not preferred in patients with ASCVD on statins due to an increased risk of myopathy when combined with statins. Instead, a PCSK9 inhibitor (evolocumab) is a better option for LDL reduction.</p>\r\n<p><strong>(Choice D) Only 1 and 3</strong> - This omits both evolocumab and bempedoic acid, which are essential for further LDL reduction in high-risk ASCVD patients. Gemfibrozil is not preferred due to its interaction with statins.</p>\r\n<p><strong><u>Key takeaway</u></strong></p>\r\n<ul>\r\n<li><strong>Alirocumab and evolocumab are monoclonal antibodies against PCSK 9 and are approved for familial hypercholesterolemia as an adjunct to diet and maximally tolerated statin therapy.</strong></li>\r\n<li><strong>A fixed-dose combination of bempedoic acid and ezetimibe is approved as an adjunct to diet and maximally tolerated statin therapy to further lower LDL-C in patients with HeFH or established ASCVD. </strong></li>\r\n</ul>",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Chloroquine</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Primaquine</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Artemether</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Sulfadoxine-pyrimethamine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs is not given in uncomplicated malaria?</span></p>",
      "unique_key": "DT1317849",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317849,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><em><u>Uncomplicated falciparum malaria </u></em></strong></p>\r\n<ul>\r\n<li><strong><em>Oral artemisinins are indicated for the treatment of all cases of uncomplicated falciparum malaria (CQ-resistant as well as sensitive) as ACT.</em></strong></li>\r\n<li><em>Even when used alone, they are almost 100% effective, but because of short duration of action recrudescence rates are high.</em></li>\r\n<li><em>In order to preserve their powerful antimalarial activity and to reduce recrudescence rates, they must be used in combination with a longacting </em><em>schizontocide which acts by a different mechanism.</em></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/202503082aa17308-aad2-44c2-9115-ca99cb29aeda.jpg\">\r\n<p><strong><u>Primaquine in Falciparum malaria</u></strong></p>\r\n<ul>\r\n<li>A single 45 mg dose of primaquine is given with the curative dose of ACT or CQ to kill the gametes and cut down transmission to mosquito.</li>\r\n<li>However, the <strong>recent WHO guideline has advised a lower 15 mg (0.25 mg/kg) single dose for this purpose.</strong></li>\r\n</ul>\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice A) Chloroquine</strong> - Chloroquine is the first-line drug for treating uncomplicated malaria in chloroquine-sensitive cases, particularly Plasmodium vivax and Plasmodium ovale infections. However, it is ineffective in chloroquine-resistantPlasmodium falciparum malaria.</p>\r\n<p><strong>(Choice C) Artemether</strong> - Artemether, as part of artemisinin-based combination therapy (ACT), is a key treatment for uncomplicated falciparum malaria in both chloroquine-sensitive and chloroquine-resistant cases.</p>\r\n<p><strong>(Choice D) Sulfadoxine-pyrimethamine</strong> - This combination is used as part of treatment regimens for uncomplicated falciparum malaria, particularly in combination with artemisinins to prevent resistance and improve cure rates.</p>\r\n<p><strong><u>Key takeaway</u></strong></p>\r\n<ul>\r\n<li><strong>Oral artemisinins are indicated for the treatment of all cases of uncomplicated falciparum malaria (CQ-resistant as well as sensitive) as ACT.</strong></li>\r\n<li><strong>Primaquine is given with the curative dose of ACT or CQ to kill the gametes and cut down transmission to mosquito. </strong></li>\r\n</ul>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Ibalizumab</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Maraviroc</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Elvitegravir</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Fosamprenavir</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Drug that binds to CD4 and has action on both CCR5 and CXCR4 tropic HIV infection: </span></p>",
      "unique_key": "DT1317850",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317850,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><u>ENTRY inhibitors</u></strong></p>\r\n<ul>\r\n<li><strong>Gp41 present on envelope of HIV binds to CD4 receptors on the surface of CD4 cells. The entry of the virus inside the cell is facilitated by co-receptors (CCR5 or CXCR-4) present on CD4 cells.</strong></li>\r\n<li><strong>Ibalizumab is a monoclonal antibody against CD4 receptors. When given </strong><strong>intravenously, it can inhibit the fusion of HIV with CD4 cells.</strong></li>\r\n<li><strong>Enfuvirtide </strong>is a drug that <strong>binds to Gp 41 subunit of HIV </strong>envelope protein and inhibits the fusion of viral and host cell membranes. It is not effective against HIV-2</li>\r\n<li><strong>Maraviroc </strong>is the first CCR5 co-receptor antagonist to be approved for use.</li>\r\n<li>It is only active against \"CCR-5-tropic virus\" and thus, a co-receptor tropism assay should be performed before starting maraviroc.</li>\r\n</ul>\r\n<p><strong><u>Ibalizumab </u></strong></p>\r\n<ul>\r\n<li><strong>Ibalizumab is a humanized monoclonal antibody that binds to the CD4 extracellular domain 2, causing steric hindrance of a conformational change in the gp120-CD4 complex necessary for HIV fusion and entry</strong></li>\r\n<li><u>Ibalizumab is approved for use in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are failing their current antiretroviral regimen.</u></li>\r\n<li>Ibalizumab retains activity against viruses that have become resistant to antiretroviral agents of other classes because of its unique mechanism of action.</li>\r\n</ul>\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice B) Maraviroc</strong> - Maraviroc is a <strong>CCR5 co-receptor antagonist</strong> that blocks the interaction between HIV gp120 and <strong>CCR5</strong>. However, it is <strong>not active against CXCR4-tropic HIV</strong>, so a <strong>co-receptor tropism assay</strong> is required before use.</p>\r\n<p><strong>(Choice C) Elvitegravir</strong> - Elvitegravir is an <strong>integrase inhibitor</strong>, meaning it blocks the integration of viral DNA into the host genome. It does not function at the entry stage and has no effect on <strong>CCR5 or CXCR4 tropic HIV</strong>.</p>\r\n<p><strong>(Choice D) Fosamprenavir</strong> - Fosamprenavir is a <strong>protease inhibitor</strong> that prevents the cleavage of viral polyproteins needed for the maturation of new viral particles. It does not target HIV entry mechanisms.</p>\r\n<p><strong><u>Key takeaway</u></strong></p>\r\n<p><strong>Ibalizumab is a monoclonal antibody against CD4 receptors. When given </strong><strong>intravenously, it can inhibit the fusion of HIV with CD4 cells.</strong></p>",
      "correct_choice_id": 41,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Lacosamide</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Lamotrigine</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Topiramate</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Phenytoin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Drug acting on sodium channels and potentiating slow sodium inactivation: </span></p>",
      "unique_key": "DT1317852",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317852,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><u>Lacosamide </u></strong></p>\r\n<ul>\r\n<li>This recently introduced <strong>antiseizure drug is indicated in adults only for add-on therapy of partial seizures with or without generalization.</strong></li>\r\n<li>It <strong>acts by enhancing Na+ channel inactivation and suppressing repetitive firing of neurones.</strong></li>\r\n<li>Lacosamide is metabolized by CYP2C19 and excreted in urine with t&frac12; ~ 12 hours.</li>\r\n<li>No alteration in dose of companion antiepileptic drug is needed, because it neither induces nor inhibits drug metabolizing enzymes.</li>\r\n<li>Adverse effects are <u>ataxia, vertigo, diplopia, tremor, depression and cardiac arrhythmia.</u></li>\r\n</ul>\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice B) Lamotrigine</strong> - Lamotrigine also acts on <strong>sodium channels</strong>, but it primarily inhibits <strong>fast inactivation</strong> rather than potentiating <strong>slow sodium inactivation</strong>. Additionally, it inhibits <strong>glutamate release</strong>, contributing to its broad-spectrum antiepileptic effect.</p>\r\n<p><strong>(Choice C) Topiramate</strong> - Topiramate has multiple mechanisms of action, including <strong>blocking sodium channels</strong>, <strong>enhancing GABA activity</strong>, and <strong>inhibiting AMPA/kainate glutamate receptors</strong>. However, it does not specifically <strong>potentiate slow sodium inactivation</strong> like lacosamide.</p>\r\n<p><strong>(Choice D) Phenytoin</strong> - Phenytoin is a <strong>classic sodium channel blocker</strong> that primarily works by <strong>stabilizing fast inactivation</strong> of Na+ channels, reducing neuronal excitability. It does not <strong>enhance slow sodium inactivation</strong> like lacosamide.</p>\r\n<p><strong><u>Key takeaway</u></strong></p>\r\n<ul>\r\n<li><strong>Lacosamide is an antiseizure drug is indicated in adults only for add-on therapy of partial seizures with or without generalization. </strong></li>\r\n<li><strong>It acts by enhancing Na+ channel inactivation and suppressing repetitive firing of neurones. </strong></li>\r\n</ul>",
      "correct_choice_id": 51,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Palbociclib</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Rucaparib</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Regorafenib</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Vandetanib</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Inhibitors of PARP (poly ADP ribose polymerase) are approved for BRCA-positive breast cancer. Which of the following drugs is used? </span></p>",
      "unique_key": "DT1317853",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317853,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><u>PARP inhibitors</u></strong></p>\r\n<ul>\r\n<li><strong>Olaparib </strong>and <strong>rucaparib </strong>are poly ADP-ribose polymerase (PARP) inhibitors and are used for oral treatment of <strong>ovarian cancer.</strong></li>\r\n<li><strong>Niraparib </strong>is new drug in this group that is indicated for ovarian, fallopian tube or primary peritoneal cancer.</li>\r\n<li><strong>Talazoparib </strong>has been recently approved for advanced breast carcinoma with BRCA mutations.</li>\r\n</ul>\r\n<p><strong><u>Rucaparib </u></strong></p>\r\n<ul>\r\n<li>Rucaparib is an orally bioavailable inhibitor of PARP1-3.</li>\r\n<li><strong>Rucaparib approved for the treatment of patients with <u>advanced ovarian cancer with BRCA mutations</u> and is used in the maintenance treatment of these patients after a partial response to platinum-based chemotherapy</strong>.</li>\r\n<li>Other uses include patients with <u>BRCA-mutated, metastatic, castration-resistant prostate cancer after endocrine and taxane-based therapy.</u></li>\r\n<li>Rucaparib is metabolized primarily by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4</li>\r\n</ul>\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice A) Palbociclib</strong> - Palbociclib is a <strong>cyclin-dependent kinase (CDK) 4/6 inhibitor</strong> used in the treatment of <strong>hormone receptor-positive (HR+), HER2-negative advanced breast cancer</strong>. It does not act as a <strong>PARP inhibitor</strong> and is not specifically indicated for BRCA-positive cancers.</p>\r\n<p><strong>(Choice C) Regorafenib</strong> - Regorafenib is a <strong>multi-kinase inhibitor</strong> that targets <strong>angiogenesis and tumor growth pathways</strong>. It is used in <strong>metastatic colorectal cancer, gastrointestinal stromal tumors (GISTs), and hepatocellular carcinoma (HCC)</strong> but does not have a role in BRCA-mutated breast cancer.</p>\r\n<p><strong>(Choice D) Vandetanib</strong> - Vandetanib is a <strong>tyrosine kinase inhibitor (TKI)</strong> targeting VEGFR, EGFR, and RET signaling. It is primarily used for the treatment of <strong>medullary thyroid carcinoma</strong> and has no direct relevance to <strong>BRCA-mutated breast cancer</strong>.</p>\r\n<p><strong><u>Key takeaway</u></strong></p>\r\n<p><strong>Rucaparib is approved for the treatment of patients with advanced ovarian cancer with BRCA mutations and is used in the maintenance treatment of these patients after a partial response to platinum-based chemotherapy</strong></p>",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Filgotinib</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Ozanimod</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Tofacitinib</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Infliximab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A known case of ulcerative colitis is not responding to anti-TNF alpha agent. Which JAK inhibitor is preferred in moderate to severe ulcerative colitis?</span></p>",
      "unique_key": "DT1317854",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317854,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><u>Tofacitinib </u></strong></p>\r\n<ul>\r\n<li><u>Tofacitinib </u><u>is an oral JAK inhibitor approved for use in rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular juvenile arthritis in adults. </u></li>\r\n<li><strong><u>Janus Kinase Inhibitors</u></strong></li>\r\n<li><strong>Tofacitinib </strong>and <strong>baricitinib </strong>are inhibitors of Janus kinase 3.</li>\r\n<li>These are <strong>approved for severe RA refractory to methotrexate</strong>. These are effective orally.</li>\r\n<li>Like TNF-&alpha; inhibitors, screening of patients for latent TB must be done prior to receiving these drugs.</li>\r\n</ul>\r\n<p><strong><u>Tofacitinib </u></strong></p>\r\n<ul>\r\n<li>It is a new synthetic drug approved for severe cases of RA that are not responding to Mtx.</li>\r\n<li>Tofacitinib can be used alone or concurrently with Mtx, but should not be combined with azathioprine, cyclosporine or biological DMARDs.</li>\r\n<li>It <strong>is a JAK-3 and JAK-1 kinase inhibitor, interferes with the JAK-STAT signaling pathway and DNA transcription, production of inflammatory mediators and release of cytokines is inhibited.</strong></li>\r\n<li>Adverse effects are <u>headache, insomnia, diarrhoea, hypertension, anaemia, </u><u>susceptibility to respiratory infections, flaring of tuberculosis and liver damage.</u></li>\r\n</ul>\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice A) Filgotinib</strong> - Filgotinib is a <strong>selective JAK1 inhibitor</strong> that is approved for <strong>rheumatoid arthritis</strong> but is still under investigation for <strong>ulcerative colitis</strong>. It is not currently the preferred JAK inhibitor for <strong>moderate to severe ulcerative colitis</strong>.</p>\r\n<p><strong>(Choice B) Ozanimod</strong> - Ozanimod is a <strong>sphingosine-1-phosphate (S1P) receptor modulator</strong>, approved for <strong>relapsing multiple sclerosis (MS) and ulcerative colitis</strong>. While it is used for <strong>ulcerative colitis</strong>, it works by reducing lymphocyte migration rather than by JAK inhibition.</p>\r\n<p><strong>(Choice D) Infliximab</strong> - Infliximab is a <strong>TNF-&alpha; inhibitor</strong> commonly used in <strong>moderate to severe ulcerative colitis</strong>. However, since the patient in this case <strong>is not responding to anti-TNF&alpha; therapy</strong>, switching to another TNF inhibitor like infliximab would not be the preferred approach.</p>\r\n<p><strong><u>Key takeaway</u></strong></p>\r\n<p><strong>Tofacitinib is an oral JAK inhibitor approved for use in rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular juvenile arthritis in adults. </strong></p>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Organophosphorus - Physostigmine</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Benzodiazepines - Flumazenil </span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Arsenic - Desferrioxamine</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Atropine - L-carnitine </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Correctly match antidote with toxicity: </span></p>",
      "unique_key": "DT1317856",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317856,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><u>Flumazenil </u></strong></p>\r\n<ul>\r\n<li>It is a <u>BZD analogue which has little intrinsic activity (practically no effect on normal subjects), but competes with BZD agonists as well as inverse agonists for the BZD receptor and reverses their depressant or stimulant effects respectively.</u></li>\r\n</ul>\r\n<p><strong><u>Uses</u></strong></p>\r\n<ol>\r\n<li><strong><u> To reverse BZD anaesthesia </u></strong>\r\n<ul>\r\n<li>Patients anaesthetized/sedated with a BZD wakeup, get oriented and regain motor control within 1 min of an i.v. injection of 0.3-1 mg of flumazenil.</li>\r\n</ul>\r\n</li>\r\n<li><strong><u> BZD overdose </u></strong>\r\n<ul>\r\n<li>Majority of patients of BZD overdose require only supportive measures like patent airway, maintenance of BP, cardiac and renal function (by fluid transfusion, etc.).</li>\r\n<li>Flumazenil blocks the hypnotic effect of zolpidem-like non-BZDs as well.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong><u>Adverse effects </u></strong></p>\r\n<ul>\r\n<li><u>Side effects noted during use of flumazenil as a BZD-antagonist are-agitation, discomfort, fearfulness, anxiety, coldness and withdrawal seizures.</u></li>\r\n</ul>\r\n<p><strong><u>TREATMENT OF POISONINGS</u></strong></p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/20250308d2455e1c-0692-461b-a649-ffbdfa80a0fe.jpg\">\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice A) Organophosphorus - Physostigmine</strong> &rarr; <strong>Incorrect</strong></p>\r\n<ul>\r\n<li>Organophosphorus poisoning causes <strong>excess cholinergic activity</strong> by <strong>inhibiting acetylcholinesterase</strong>.</li>\r\n<li>The correct antidote is <strong>atropine</strong> (a muscarinic antagonist) and <strong>pralidoxime (2-PAM)</strong>, which <strong>reactivates acetylcholinesterase</strong>.</li>\r\n<li><strong>Physostigmine is a cholinesterase inhibitor</strong>, which would worsen the poisoning instead of treating it.</li>\r\n</ul>\r\n<p><strong>(Choice C) Arsenic - Desferrioxamine</strong> &rarr; <strong>Incorrect</strong></p>\r\n<ul>\r\n<li>Arsenic poisoning is treated with <strong>dimercaprol (BAL) or succimer (DMSA)</strong>, which are <strong>chelating agents that bind arsenic</strong> and facilitate excretion.</li>\r\n<li><strong>Desferrioxamine</strong> is used for <strong>iron toxicity</strong>, not arsenic poisoning.</li>\r\n</ul>\r\n<p><strong>(Choice D) Atropine - L-carnitine</strong> &rarr; <strong>Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Atropine toxicity</strong> is characterized by <strong>anticholinergic symptoms</strong> (dry mouth, tachycardia, mydriasis, hallucinations, etc.).</li>\r\n<li>The correct antidote is <strong>physostigmine</strong>, a <strong>cholinesterase inhibitor that increases acetylcholine levels</strong>.</li>\r\n<li><strong>L-carnitine is not used in atropine toxicity</strong>; it is primarily used for <strong>carnitine deficiency disorders</strong>.</li>\r\n</ul>\r\n<p><strong><u>Key takeaway</u></strong></p>\r\n<p><strong>Flumazenil is a BZD analogue which has little intrinsic activity, but competes with BZD agonists as well as inverse agonists for the BZD receptor and reverses their depressant or stimulant effects respectively. </strong></p>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Systemic infusion of alpha blocker </span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Systemic infusion of smooth muscle relaxant</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Loss of lumbar sympathetic outflow</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Systemic infusion of beta 1 adrenergic agonist </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following will lead to a decrease in diastolic blood pressure?\t</span></p>",
      "unique_key": "DT1317857",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317857,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><u>General Functions of the Autonomic Nervous System</u></strong></p>\r\n<ul>\r\n<li>The autonomic nervous system is the primary regulator of the constancy of the internal environment of the organism, or the maintenance of homeostasis.</li>\r\n<li>The sympathetic system and its associated adrenal medulla are not essential to life in a controlled environment, but the lack of sympathoadrenal functions becomes evident under circumstances of stress.</li>\r\n<li>For example, in the <strong>absence of the sympathetic system, body temperature cannot be regulated when environmental temperature varies; the concentration of glucose in blood does not rise in response to urgent need; compensatory vascular responses to hemorrhage, oxygen deprivation, excitement, and exercise are lacking; and resistance to fatigue is lessened.</strong></li>\r\n<li>The sympathoadrenal system can discharge as a unit.</li>\r\n<li><strong>Heart rate is accelerated; blood pressure rises; blood flow is shifted from the skin and splanchnic region to the skeletal and cardiac muscles; blood glucose rises; the bronchioles and pupils dilate; and the organism is better prepared for \"fight or flight.\" </strong></li>\r\n<li>The upright posture imposes a unique physiologic stress upon humans; most, although not all, syncopal episodes occur from a standing position.</li>\r\n<li>Standing results in pooling of 500-1000 mL of blood in the lower extremities, buttocks, and splanchnic circulation.</li>\r\n<li>The <strong>dependent pooling leads to a decrease in venous return to the heart and reduced ventricular filling that result in diminished cardiac output and blood pressure</strong>.</li>\r\n<li>These hemodynamic changes provoke a compensatory reflex response, initiated by the baroreceptors in the carotid sinus and aortic arch, resulting in increased sympathetic outflow and decreased vagal nerve activity.</li>\r\n<li>The reflex increases peripheral resistance, venous return to the heart, and cardiac output and thus limits the fall in blood pressure.</li>\r\n<li>Syncope is a consequence of global cerebral hypoperfusion and thus represents a failure of cerebral blood flow autoregulatory mechanisms.</li>\r\n</ul>\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice A) Systemic infusion of alpha blocker &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Alpha-blockers (e.g., prazosin, phentolamine) inhibit &alpha;1-adrenergic receptors</strong>, which normally mediate <strong>vasoconstriction</strong>.</li>\r\n<li><strong>Blocking alpha receptors causes vasodilation, leading to a fall in both systolic and diastolic blood pressure.</strong></li>\r\n<li>However, <strong>the drop in diastolic BP is usually accompanied by a compensatory increase in heart rate (reflex tachycardia), which limits the decrease in BP</strong>.</li>\r\n</ul>\r\n<p><strong>(Choice B) Systemic infusion of smooth muscle relaxant &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Smooth muscle relaxants (e.g., nitrates, hydralazine) primarily act on arterioles</strong> and reduce <strong>systemic vascular resistance</strong>, leading to a decrease in <strong>systolic blood pressure more than diastolic blood pressure</strong>.</li>\r\n<li><strong>Diastolic BP does decrease</strong>, but <strong>not as much as in the case of complete loss of sympathetic outflow</strong>.</li>\r\n<li>These drugs also trigger <strong>baroreceptor reflex-mediated tachycardia</strong>, which helps <strong>maintain perfusion pressure</strong>.</li>\r\n</ul>\r\n<p><strong>(Choice D) Systemic infusion of beta-1 adrenergic agonist &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Beta-1 adrenergic agonists (e.g., dobutamine, isoproterenol) increase heart rate and contractility, leading to increased cardiac output.</strong></li>\r\n<li><strong>This increases systolic blood pressure but does not significantly decrease diastolic blood pressure.</strong></li>\r\n<li>In some cases, beta-agonists <strong>reduce diastolic BP slightly due to reduced systemic vascular resistance</strong>, but the net effect is usually an <strong>increase in mean arterial pressure (MAP)</strong>.</li>\r\n</ul>\r\n<p><strong>Key Takeaway:</strong></p>\r\n<ul>\r\n<li>Loss of lumbar sympathetic outflow leads to the most significant drop in diastolic blood pressure due to unopposed vasodilation and loss of sympathetic vascular tone.</li>\r\n<li>Alpha-blockers and smooth muscle relaxants can lower diastolic BP but usually with compensatory mechanisms limiting the drop.</li>\r\n<li>Beta-1 agonists do not significantly decrease diastolic BP, as they primarily increase cardiac output.</li>\r\n</ul>",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Given for XDR-TB with bedaquiline and linezolid</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Contraindicated in patients taking drugs inducing CYP 2C19 enzymes </span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Acts by reactive oxygen species </span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">For resistant malaria </span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">True statement for pretomanid:</span></p>",
      "unique_key": "DT1317859",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317859,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><u>Bicyclic Nitroimidazoles</u></strong></p>\r\n<ul>\r\n<li><strong>Delamanid and Pretomanid </strong>are bicyclic nitroimidazopyrans that are being used in the treatment of XDR- and MDR-TB.</li>\r\n<li><strong><u>Pretomanid is FDA-approved for the treatment of XDR-TB in combination with bedaquiline and linezolid. </u></strong></li>\r\n<li>Delamanid is licensed by the European Medicines Agency for the treatment of MDR-TB.</li>\r\n</ul>\r\n<p><strong><u>Mechanisms of Action</u></strong></p>\r\n<ul>\r\n<li><u>Pretomanid has two mechanisms of action. First, under aerobic conditions, it inhibits M. tuberculosis mycolic acid and protein synthesis at the step between hydroxymycolate and ketomycolate </u></li>\r\n<li>Systemic exposures of pretomanid and delamanid increase when taken with food. Delamanid metabolism involves albumin.</li>\r\n<li>Delamanid is not metabolized by CYP4s.</li>\r\n<li><strong>Pretomanid is metabolized approximately 20% by CYP3A; coadministration of rifampin reduces pretomanid exposures</strong></li>\r\n</ul>\r\n<p><strong><u>Untoward Effects </u></strong></p>\r\n<ul>\r\n<li>Delamanid can cause headaches and insomnia. It has a modest effect on the QT interval on ECG.</li>\r\n<li>Pretomanid has been associated with hepatotoxicity</li>\r\n</ul>\r\n<p><strong><u>Drug interactions</u></strong></p>\r\n<ul>\r\n<li><strong>Pretomanid is metabolized in part by CYP3A, so coadministration with strong or moderate CYP3A inducers should be avoided. </strong></li>\r\n<li>Delamanid displays low bioavailability, so to maximize absorption, it should be taken with food and separated from dosing of other medications, if possible.</li>\r\n</ul>\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice B) Contraindicated in patients taking drugs inducing CYP2C19 enzymes &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Pretomanid is primarily metabolized by CYP3A, not CYP2C19.</strong></li>\r\n<li><strong>Drugs that induce CYP3A (e.g., rifampin) reduce pretomanid levels</strong>, leading to decreased efficacy.</li>\r\n<li>There is <strong>no major contraindication specifically related to CYP2C19 enzyme induction.</strong></li>\r\n</ul>\r\n<p><strong>(Choice C) Acts by reactive oxygen species &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Pretomanid has two mechanisms of action:</strong>\r\n<ol>\r\n<li><strong>Aerobic conditions:</strong> Inhibits mycolic acid and protein synthesis, disrupting <strong>cell wall formation</strong> of Mycobacterium tuberculosis.</li>\r\n<li><strong>Anaerobic conditions:</strong> Leads to <strong>formation of nitric oxide</strong>, which is toxic to the bacteria.</li>\r\n</ol>\r\n</li>\r\n<li>While nitric oxide plays a role in its action, <strong>it does not directly act through reactive oxygen species (ROS).</strong></li>\r\n</ul>\r\n<p><strong>(Choice D) For resistant malaria &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Pretomanid is not used for malaria-</strong>it is exclusively indicated for <strong>drug-resistant tuberculosis.</strong></li>\r\n<li><strong>Antimalarial drugs (e.g., artemisinin-based combination therapies, quinine, mefloquine)</strong> are the standard treatments for resistant malaria, not pretomanid.</li>\r\n</ul>\r\n<p><strong><u>Key takeaway</u></strong></p>\r\n<ul>\r\n<li><strong>Pretomanid is FDA-approved for the treatment of XDR-TB in combination with bedaquiline and linezolid. </strong></li>\r\n<li><strong>Pretomanid is metabolized in part by CYP3A, so co-administration with strong or moderate CYP3A inducers should be avoided. </strong></li>\r\n</ul>",
      "correct_choice_id": 101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute oral overdose results primarily in cerebellar and vestibular symptoms, and high doses have been associated with marked cerebellar atrophy</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Phenytoin causes cardiotoxicity and nephrotoxicity in old and young patients</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">The complications can be minimized by administering fosphenytoin at a rate of less than 250 mg of phenytoin sodium equivalent per minute </span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Given to all patients with seizures regardless of cardiac arrhythmia, hypotension, and/or sinus depression</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Choose the correct option regarding phenytoin: </span></p>",
      "unique_key": "DT1317860",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317860,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong><u>Over dose toxicity due to higher plasma concentration of phenytoin produces</u></strong></p>\r\n<ul>\r\n<li><strong>Cerebellar and vestibular manifestations: ataxia, vertigo, diplopia, nystagmus.</strong></li>\r\n<li><strong>Drowsiness, behavioural alterations, mental confusion, hallucinations, disorientation and rigidity</strong></li>\r\n<li>Epigastric pain, nausea and vomiting</li>\r\n<li>Intravenous injection of phenytoin sodium can cause local <strong>vascular injury &rarr; intimal damage and thrombosis of the vein &rarr; edema and&nbsp;</strong><strong>discolouration</strong> of the injected limb. Tissue necrosis occurs if the solution extravasates.</li>\r\n<li><u>Fall in BP and cardiac arrhythmias occur only on i.v. injection which, therefore, must be given under continuous ECG monitoring.</u></li>\r\n</ul>\r\n<p><strong><u>Adverse effects of Phenytoin</u></strong></p>\r\n<ul>\r\n<li><strong>Gum hypertrophy</strong>: Commonest (20% incidence), more in younger patients. It is due to <strong>overgrowth of gingival collagen fibres.</strong></li>\r\n<li><strong>Hirsutism, coarsening of facial features</strong> (troublesome in young girls), acne.</li>\r\n<li><strong>Hypersensitivity reactions</strong> are-rashes, <strong>DLE, lymphadenopathy; neutropenia </strong>is rare but requires discontinuation of therapy.</li>\r\n<li><strong>Megaloblastic anaemia and osteomalacia</strong> can occur on long term use due to <u>interference with folate absorption and vit. D activation respectively.</u></li>\r\n<li>Administered during pregnancy, phenytoin can produce <strong>'foetal hydantoin syndrome' (hypoplastic phalanges, cleft palate, harelip, microcephaly), which is probably caused by its arene-oxide metabolite</strong>.</li>\r\n</ul>\r\n<p><strong><u>ADRs of Phenytoin</u></strong></p>\r\n<p><strong><u>Mnemonic [HOT MALIKA]</u></strong></p>\r\n<ul>\r\n<li><strong>H </strong>- <strong>H</strong>irsutism, Hypertrophy of gums</li>\r\n<li><strong>O</strong> -<strong> O</strong>steomalacia</li>\r\n<li><strong>T</strong> - <strong>T</strong>eratogenicity [Fetal Hydantoin syndrome]</li>\r\n<li><strong>M - M</strong>egaloblastic Anemia [&darr; Folate levels]</li>\r\n<li><strong>A - A</strong>rrhythmia [Only in overdose]</li>\r\n<li><strong>L - L</strong>ymph node enlargement</li>\r\n<li><strong>I - &darr; I</strong>nsulin (avoided in Diabetus mellitus- Precipitates hyperglycemia)</li>\r\n<li><strong>K -</strong> &darr; Vitamin <strong>K </strong>levels</li>\r\n<li><strong>A - A</strong><strong>taxias, vertigo [cerebellar symptoms</strong><strong>] [only at high dose]</strong></li>\r\n</ul>\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice B) Phenytoin causes cardiotoxicity and nephrotoxicity in old and young patients &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Phenytoin is primarily associated with cardiovascular toxicity in IV form, not oral use.</strong>\r\n<ul>\r\n<li>IV <strong>phenytoin</strong> can cause <strong>hypotension, cardiac arrhythmias, and AV block</strong>, especially if administered too rapidly.</li>\r\n<li><strong>Oral phenytoin does not typically cause significant cardiotoxicity</strong> at therapeutic doses.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Nephrotoxicity is not a common adverse effect</strong> of phenytoin.</li>\r\n</ul>\r\n<p><strong>(Choice C) The complications can be minimized by administering fosphenytoin at a rate of less than 250 mg of phenytoin sodium equivalent per minute &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Fosphenytoin (a prodrug of phenytoin) is safer for IV use</strong> and is preferred over phenytoin due to lower risk of local tissue injury.</li>\r\n<li><strong>Recommended administration rate:</strong>\r\n<ul>\r\n<li><strong>Fosphenytoin:</strong> Should not exceed <strong>150 mg of phenytoin sodium equivalent (PE) per minute</strong> to prevent cardiovascular complications.</li>\r\n<li><strong>Phenytoin:</strong> Should not exceed <strong>50 mg/min</strong> due to the risk of <strong>severe hypotension and arrhythmias</strong>.</li>\r\n</ul>\r\n</li>\r\n<li>The <strong>\"250 mg/min\" value is incorrect</strong> and would be dangerously high.</li>\r\n</ul>\r\n<p><strong>(Choice D) Given to all patients with seizures regardless of cardiac arrhythmia, hypotension, and/or sinus depression &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Phenytoin should be avoided in patients with pre-existing cardiac conduction abnormalities</strong> such as:\r\n<ul>\r\n<li><strong>Bradycardia</strong></li>\r\n<li><strong>Heart block</strong></li>\r\n<li><strong>Hypotension</strong></li>\r\n<li><strong>Sinus node dysfunction</strong></li>\r\n</ul>\r\n</li>\r\n<li><strong>Phenytoin can cause dose-dependent cardiac toxicity, especially with rapid IV administration.</strong></li>\r\n</ul>\r\n<p><strong><u>Key takeaway</u></strong></p>\r\n<ul>\r\n<li><strong>Over dose toxicity due to higher plasma concentration of phenytoin produces Cerebellar and vestibular manifestations: ataxia, vertigo, diplopia, nystagmus</strong></li>\r\n<li><strong>Drowsiness, behavioural alterations, mental confusion, hallucinations, disorientation and rigidity</strong></li>\r\n</ul>\r\n",
      "correct_choice_id": 111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Ganaxolone</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Tiagabine</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Felbamate</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Stiripentol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which drug acts on the marked receptor (image: showed GAT inhibition)? <br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/2025020809c51056-581f-4f0f-9fe4-22e9a6c5b4be.jpg\"></span></p>",
      "unique_key": "DT1317862",
      "question_audio": null,
      "question_video": null,
      "map_id": 1317862,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Tiagabine </strong>is indicated for adjunctive treatment of partial seizures.</li>\r\n<li>It is a <strong>rationally designed </strong>drug as an inhibitor of GABA uptake (by inhibiting GAT-1).</li>\r\n</ul>\r\n<p><strong><u>Tiagabine </u></strong></p>\r\n<ul>\r\n<li>This <strong>newer anticonvulsant potentiates GABA mediated neuronal inhibition by blocking GABA transporter</strong></li>\r\n<li><strong>GAT-1 which removes synaptically released GABA into neurones and glial cells. </strong></li>\r\n<li>Kindled seizures are suppressed with less marked effect on maximal electroshock.</li>\r\n<li>Currently <u>it is approved only for add-on therapy of partial seizures with or without secondary generalization, when not adequately controlled by standard antiepileptic drugs alone.</u></li>\r\n<li>Side effects are <u>mild sedation, nervousness, asthenia, amnesia, dermatitis and abdominal pain.</u></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/20250208a88c3841-1ed1-4da7-bae9-091224bb971e.jpg\">\r\n<p><strong>Incorrect Choices Explanation:</strong></p>\r\n<p><strong>(Choice A) Ganaxolone &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Ganaxolone is a neurosteroid that acts as a positive allosteric modulator of GABA-A receptors.</strong></li>\r\n<li>Unlike Tiagabine, <strong>it does not inhibit GABA reuptake (GAT-1), but rather enhances GABAergic transmission directly.</strong></li>\r\n<li><strong>Indications:</strong>\r\n<ul>\r\n<li>Used in <strong>epilepsy syndromes</strong> such as <strong>CDKL5 deficiency disorder</strong>.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>(Choice C) Felbamate &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Felbamate is an antiepileptic drug that primarily acts by blocking NMDA (N-methyl-D-aspartate) receptors.</strong></li>\r\n<li>It also <strong>modulates GABA-A receptors but does not inhibit GABA reuptake via GAT-1.</strong></li>\r\n<li><strong>Indications:</strong>\r\n<ul>\r\n<li>Reserved for <strong>severe, refractory epilepsy</strong> due to its risk of <strong>aplastic anemia and liver failure</strong>.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>(Choice D) Stiripentol &rarr; Incorrect</strong></p>\r\n<ul>\r\n<li><strong>Stiripentol enhances GABAergic neurotransmission by increasing GABA-A receptor activity.</strong></li>\r\n<li>It also <strong>inhibits the metabolism of clobazam and other anticonvulsants</strong>, increasing their effectiveness.</li>\r\n<li><strong>Indications:</strong>\r\n<ul>\r\n<li>Used in <strong>Dravet syndrome</strong>, a severe form of epilepsy.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong><em><u>Key takeaway</u></em></strong></p>\r\n<p><strong><em>Tiagabine is indicated for adjunctive treatment of partial seizures. It is a rationally designed drug as an inhibitor of GABA uptake (by inhibiting GAT-1)</em></strong></p>",
      "correct_choice_id": 122,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}